Compare Mesoblast Limited (MESO) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs ProShares Ultra Gold ETF — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while ProShares Ultra Gold ETF trades at $46.45 (market cap $716.59M). The key difference: Mesoblast Limited is far larger — about 2.4× ProShares Ultra Gold ETF's market cap, and Mesoblast Limited is more actively traded (239,027 versus 2,592,878). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and ProShares Ultra Gold ETF for 23 Days on average.
| MESO | UGL | |
|---|---|---|
Market Cap | $1.75B | $716.59M |
Volume | 239,027 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $20.96 | $85.62 |
52-Week Low | $13.19 | $42.79 |
Typical Hold Time | 15 Days | 23 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
UGL is trading at $46.45, up 4.55% today, but faces significant technical headwinds with a bearish overall signal. The stock shows neutral momentum oscillators but bearish moving averages, with key resistance at $46. Current financial ratios are unavailable, limiting fundamental assessment. Recent gold market volatility driven by Treasury yields and Fed policy expectations creates uncertainty for gold-related equities.
The outlook remains cautious given technical weakness and macroeconomic pressures on gold prices. Investment opportunity exists for contrarian investors if gold regains momentum, but risks include persistent rate hike expectations and dollar strength. Stock-specific fundamentals require verification through SEC filings for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
